Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Cancer of Breast|Trastuzumab Emtansine|Trastuzumab Deruxtecan
progression-free survival (PFS), PFS will be assessed by physicians as per routine clinical practice. CT and/or MRI scans will be at baseline and every 2-4 cycles at the treating physician's discretion, reflecting the observational study design., PFS is defined as the time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, assessed up to 12 months.
objective response rate (ORR), â€¢ objective response rate (ORR), 12-month|12-month survival rate, 12-month survival rate, 12-month|time-to-discontinuation (TTD), time-to-discontinuation (TTD), 12-month|time-to-next-line-treatment (TTNT), time-to-next-line-treatment (TTNT), disregarding endocrine treatments as the maintenance, 12-month|Duration of therapy (DoT), Duration of therapy (of T-DM1) will be compared to the duration of previous therapy (T-DXd) to ensure the comparability of each treatments reflecting the tumor biology and clinical course., 12-month|Incidence of Treatment-Emergent Adverse Events, Incidence of Treatment-Emergent Adverse Events, 12-month
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea